Summary
7.89 0.23(2.94%)10/04/2024
Maravai LifeSciences Holdings Inc (MRVI)
Maravai LifeSciences Holdings Inc (MRVI)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 3.27 | -6.35 | -3.78 | 12.72 | -7.45 | -18.46 | 0.00 | -73.58 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 7.89 | |
| Open | 7.70 | |
| High | 7.90 | |
| Low | 7.62 | |
| Volume | 535,380 | |
| Change | 0.25 | |
| Change % | 3.27 | |
| Avg Volume (20 Days) | 1,030,257 | |
| Volume/Avg Volume (20 Days) Ratio | 0.52 | |
| 52 Week Range | 4.52 - 11.56 | |
| Price vs 52 Week High | -31.79% | |
| Price vs 52 Week Low | 74.45% | |
| Range | 2.40 | |
| Gap Up/Down | -0.12 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,109 | |
| EBIDTA | 450,388,992 | |
| PE Ratio | 8.3811 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 58.13 | |
| Book Value | 2.3030 | |
| Earnings Per Share | 4.7130 | |
| EPS Estimate Current Quarter | 0.3500 | |
| EPS Estimate Next Quarter | 0.3300 | |
| EPS Estimate Current Year | 1.5200 | |
| EPS Estimate Next Year | 1.5300 | |
| Diluted EPS (TTM) | 4.7130 | |
| Revenues | ||
| Profit Marging | 0.2269 | |
| Operating Marging (TTM) | 0.6330 | |
| Return on asset (TTM) | 0.0702 | |
| Return on equity (TTM) | 0.5265 | |
| Revenue TTM | 669,148,992 | |
| Revenue per share TTM | 21.0300 | |
| Quarterly Revenue Growth (YOY) | 1.3310 | |
| Quarterly Earnings Growth (YOY) | 2.7190 | |
| Gross Profit (TTM) | 204,449,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 8.3811 | |
| Forward PE | 28.9855 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 17.1449 | |
| Revenue Enterprise Value | 7.8124 | |
| EBITDA Enterprise Value | 11.2751 | |
| Shares | ||
| Shares Outstanding | 131,459,000 | |
| Shares Float | 94,601,627 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.22 | |
| Institutions (%) | 101.12 | |
08/29 10:25 EST - zacks.com
Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits
MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.
Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits
MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.
08/16 11:46 EST - reuters.com
Exclusive: Repligen in bid for reagent vendor Maravai, sources say
Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday.
Exclusive: Repligen in bid for reagent vendor Maravai, sources say
Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday.
08/12 08:05 EST - globenewswire.com
Maravai LifeSciences Announces August and September 2024 Investor Conference Schedule
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in August and September.
Maravai LifeSciences Announces August and September 2024 Investor Conference Schedule
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in August and September.
08/08 06:19 EST - seekingalpha.com
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2024 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2024 Results Conference Call August 7, 2024 5:00 PM ET Company Participants Deborah Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Chief Commercial Officer Conference Call Participants Catherine Schulte - Baird Tejas Savant - Morgan Stanley Matt Hewitt - Craig-Hallum Justin Bowers - Deutsche Bank Conor McNamara - RBC Capital Markets Michael Ryskin - Bank of America Matt Larew - William Blair Kyle Crews - UBS Operator Thank you for standing by and welcome to the Maravai LifeSciences Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2024 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2024 Results Conference Call August 7, 2024 5:00 PM ET Company Participants Deborah Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Chief Commercial Officer Conference Call Participants Catherine Schulte - Baird Tejas Savant - Morgan Stanley Matt Hewitt - Craig-Hallum Justin Bowers - Deutsche Bank Conor McNamara - RBC Capital Markets Michael Ryskin - Bank of America Matt Larew - William Blair Kyle Crews - UBS Operator Thank you for standing by and welcome to the Maravai LifeSciences Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
07/10 08:00 EST - globenewswire.com
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on Wednesday, August 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on Wednesday, August 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
07/02 16:00 EST - globenewswire.com
Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report
- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth.
Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report
- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth.
06/20 09:15 EST - accesswire.com
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability - - Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand - STONY BROOK, NY AND JUPITER, FL / ACCESSWIRE / June 20, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company (NASDAQ:MRVI) and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of the companies' previously announced Linea™ RNAP manufacturing scale-up agreement. The joint process development project resulted in an over 70% reduction in Linea RNAP manufacturing costs and the manufacture of a quantity of Linea RNAP sufficient to support Applied DNA's anticipated near-term demand for critical starting material for mRNA production.
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability - - Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand - STONY BROOK, NY AND JUPITER, FL / ACCESSWIRE / June 20, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company (NASDAQ:MRVI) and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of the companies' previously announced Linea™ RNAP manufacturing scale-up agreement. The joint process development project resulted in an over 70% reduction in Linea RNAP manufacturing costs and the manufacture of a quantity of Linea RNAP sufficient to support Applied DNA's anticipated near-term demand for critical starting material for mRNA production.
05/17 12:56 EST - zacks.com
Maravai (MRVI) Advances in RNA Research With New Collaboration
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Maravai (MRVI) Advances in RNA Research With New Collaboration
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
05/09 16:05 EST - globenewswire.com
Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the months of May and June.
Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the months of May and June.
05/08 20:59 EST - seekingalpha.com
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2024 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Debbie Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Chief Commercial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Tejas Savant - Morgan Stanley Dan Leonard - UBS Tom Peterson - Baird Matt Larew - William Blair Bob Yan - Bank of America Securities Operator Good day, ladies and gentlemen. And welcome to the First Quarter 2024 Maravai LifeSciences Earnings Conference Call.
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2024 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Debbie Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Chief Commercial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Tejas Savant - Morgan Stanley Dan Leonard - UBS Tom Peterson - Baird Matt Larew - William Blair Bob Yan - Bank of America Securities Operator Good day, ladies and gentlemen. And welcome to the First Quarter 2024 Maravai LifeSciences Earnings Conference Call.
05/08 16:05 EST - globenewswire.com
Maravai LifeSciences Reports First Quarter 2024 Financial Results
Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation
Maravai LifeSciences Reports First Quarter 2024 Financial Results
Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation
04/30 07:31 EST - businesswire.com
TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology.
TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology.
04/18 07:36 EST - businesswire.com
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production.
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production.
04/10 16:05 EST - globenewswire.com
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
03/12 16:15 EST - globenewswire.com
Maravai LifeSciences Announces March 2024 Investor Conference Schedule
SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of March.
Maravai LifeSciences Announces March 2024 Investor Conference Schedule
SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of March.
02/23 00:00 EST - seekingalpha.com
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2023 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2023 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2023 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2023 Earnings Call Transcript
02/22 16:05 EST - globenewswire.com
Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results
Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation
Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results
Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation
02/11 17:00 EST - investorplace.com
3 Doomed Biotech Stocks to Dump Before They Dive: February 2024
The unpredictable nature of the biotech industry, which frequently flirts with failure, underscores the inherent risks and rewards associated with doomed biotech stocks. The journey from drug discovery to market approval is notoriously long and uncertain.
3 Doomed Biotech Stocks to Dump Before They Dive: February 2024
The unpredictable nature of the biotech industry, which frequently flirts with failure, underscores the inherent risks and rewards associated with doomed biotech stocks. The journey from drug discovery to market approval is notoriously long and uncertain.
01/29 08:00 EST - globenewswire.com
Maravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024
SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, February 22, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
Maravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024
SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, February 22, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
11/09 08:15 EST - globenewswire.com
Maravai LifeSciences Announces November 2023 Investor Conference Schedule
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November.
Maravai LifeSciences Announces November 2023 Investor Conference Schedule
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November.